Newleos Therapeutics
Newleos Therapeutics is a clinical-stage neuroscience company developing first-in-class and best-in-class therapies to address the need for safer and more efficacious treatment options for major mental health conditions. The company's pipeline includes multiple oral small molecules licensed from Roche targeting novel mechanisms across a broad range of indications including generalized anxiety, social anxiety, substance use disorders and cognitive impairment.
Funding Round: Series A
Funding Amount: $93.5M
Date: 13-Feb-2025
Investors: Goldman Sachs Alternatives, Novo Holdings A/S, Longwood Fund, DCVC Bio, Arkin Bio Capital
Markets: Healthtech, Pharmaceuticals, Biotechnology
HQ: Boston, Massachusetts, United States
Founded: 2024
Website: http://www.newleos.com
LinkedIn: https://www.linkedin.com/company/newleos-therapeutics
Crunchbase: https://www.crunchbase.com/organization/newleos-therapeutics
Leave a Comment
Comments
No comments yet.